Michael Haddadin

Clinical trials

• Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

  Principal investigator · Recruiting · Phase 2

  University of Nebraska

  2026–2031
• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2027
• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2027
• Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2027